GlassScriptPhysician profile
Dinesh Jain
NPI 1255330361
$8,833.23
in general payments reported to CMS, 2019-2025
36 companies · $905 in 2025
The $905 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $1,797 · 2021: $2,231 · 2022: $1,289 · 2023: $533 · 2024: $603 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,157.81 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $780.64 | 2019-2025 | Jardiance |
| Pfizer INC. | $701.27 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $540.65 | 2019-2023 | Steglatro, Steglujan |
| Lilly USA, LLC | $529.69 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Janssen Pharmaceuticals, INC | $525.87 | 2019-2022 | |
| Amgen INC. | $384.96 | 2019-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $381.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.48 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $286.00 | 2019-2023 | |
| Glaxosmithkline, LLC. | $258.10 | 2019-2024 | Arexvy, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $245.15 | 2019-2020 | |
| Astellas Pharma US INC | $220.78 | 2019-2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $165.74 | 2021-2025 | |
| Amarin Pharma, INC. | $154.05 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143.17 | 2019-2025 | |
| Exact Sciences Corporation | $125.57 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $121.12 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $109.65 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $108.05 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $100.40 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $99.00 | 2020-2021 | |
| Corcept Therapeutics | $54.31 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $51.74 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.40 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $35.60 | 2019 | |
| Cmp Pharma, INC. | $32.83 | 2021 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $20.80 | 2019 | |
| Abbott Laboratories | $19.80 | 2023 | Freestyle Libre 3 |
| Radius Health, INC. | $19.44 | 2020 | |
| Ardelyx, INC. | $18.88 | 2025 | Ibsrela |
| Vivus LLC | $16.84 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.24 | 2019 | |
| Horizon Therapeutics Plc | $11.48 | 2019 | |
| Melinta Therapeutics, LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinesh Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.